TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35984339

Group type: EXPERIMENTAL
Intervention: Fear appeal voice SMS intervention (once a week for 12 months)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study: 32728771

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) lung cancer screening
Number of subjects: 543
Study: 34090781

Group type: EXPERIMENTAL
Intervention: Regenerative cell therapy
Number of subjects: 150
Study: 34343620

Group type: EXPERIMENTAL
Intervention: Yoga Skills Training (YST)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 44
Study: 34071781

Group type: EXPERIMENTAL
Intervention: Aerobic interval training with vitamin D supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vitamin D supplementation only
Number of subjects: 45

Group type: COMPARATOR
Intervention: Aerobic interval training only
Number of subjects: 45
Study: 35290454

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for patients and caregivers (Arm 2)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for patients (Arm 1)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Standard care (Arm 3)
Number of subjects: 510
Study: 33871851

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32833128

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 min of moderate-intensity weekly exercise)
Number of subjects: 83
Study: 35590284

Group type: EXPERIMENTAL
Intervention: Oral pivmecillinam (PIV) 400 mg QID for 1 week after 3 days of parenteral antibiotics
Number of subjects: 53
Study: 34375336

Group type: EXPERIMENTAL
Intervention: Oral rotavirus vaccine
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement (LNS)
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (MMS)
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA)
Number of subjects: 1525
Study: 32917784

Group type: EXPERIMENTAL
Intervention: 500 mg lanthanum carbonate thrice daily for 96 weeks
Number of subjects: 278

Group type: COMPARATOR
Intervention: Matched placebo thrice daily for 96 weeks
Number of subjects: 278
Study: 35060860

Group type: EXPERIMENTAL
Intervention: Active Learning Curriculum (ALC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Passive Learning Cohort (PLC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of ALC and PLC post-test scores
Number of subjects: 42
Study: 33622296

Group type: EXPERIMENTAL
Intervention: #10‐#15 Mechanical Glide Path super‐files with OGP motion (OGP 90°, 300 rpm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: #10‐#15 stainless steel K‐files manually
Number of subjects: 30
Study: 32805050

Group type: EXPERIMENTAL
Intervention: Whole apples
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Apple puree
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 18
Study: 34923559

Group type: EXPERIMENTAL
Intervention: VRC01 10 mg/kg
Number of subjects: 4623

Group type: EXPERIMENTAL
Intervention: VRC01 30 mg/kg
Number of subjects: 4623

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4623

Group type: EXPERIMENTAL
Intervention: VRC01 (both dosages)
Number of subjects: 4623
Study: 32184305

Group type: EXPERIMENTAL
Intervention: WEE1 inhibitor adavosertib (AZD1775) in combination with cisplatin chemotherapy preoperatively (group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: WEE1 inhibitor adavosertib (AZD1775) in combination with postoperative cisplatin-based chemoradiation (group B)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: WEE1 inhibitor adavosertib (AZD1775) in combination with cisplatin chemotherapy (group A)
Number of subjects: 21
Study: 33955686

Group type: EXPERIMENTAL
Intervention: GLPG1205 100 mg once daily for 12 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 32438192

Group type: EXPERIMENTAL
Intervention: BPA exposure
Number of subjects: 45
Study: 34115162

Group type: EXPERIMENTAL
Intervention: Methenamine hippurate
Number of subjects: 92

Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 92
Study: 33812492

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day) plus Mesalazine (2 g per day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg per day) plus Mesalazine placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aspirin placebo plus Mesalazine (2 g per day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Aspirin placebo plus Mesalazine placebo
Number of subjects: 104
Study: 33172883

Group type: EXPERIMENTAL
Intervention: FOLFOX/bevacizumab (MAVERICC)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bevacizumab (TRIBE)
Number of subjects: 648

Group type: COMPARATOR
Intervention: FOLFIRI/bevacizumab (control cohorts)
Number of subjects: 648
Study: 35732417

Group type: EXPERIMENTAL
Intervention: Shufeng Jiedu capsule (SFJDC) for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (Control)
Number of subjects: 0
Study: 33279102

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 1600

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 1600
Study: 33790308

Group type: EXPERIMENTAL
Intervention: Favipiravir 3200 mg on day 1 followed by 600 mg twice daily from day 2 to day 10
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hydroxychloroquine 800 mg on day 1 followed by 200 mg twice daily from day 2 to day 10, plus oral oseltamivir 75 mg/12 h/day for 10 days
Number of subjects: 100
Study: 32319313

Group type: EXPERIMENTAL
Intervention: Animal-Assisted Activity (AAA) intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control/usual ICU care
Number of subjects: 15
Study: 36210622

Group type: EXPERIMENTAL
Intervention: 1 mmol/L citrate
Number of subjects: 56

Group type: COMPARATOR
Intervention: 3 mmol/L acetate
Number of subjects: 56
Study: 33831342

Group type: EXPERIMENTAL
Intervention: Checkup Vision Assessment System
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard VA reference tests
Number of subjects: 108
Study: 35250032

Group type: EXPERIMENTAL
Intervention: Ld-IL2 + MTX
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo + MTX
Number of subjects: 40
Study: 32150758

Group type: EXPERIMENTAL
Intervention: TEE-guided strategy (edoxaban 60 mg once-daily or enoxaparin-warfarin)
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Non-TEE-guided strategy (edoxaban 60 mg once-daily or enoxaparin-warfarin)
Number of subjects: 2199
Study: 34496669

Group type: EXPERIMENTAL
Intervention: Pharmacist-driven medication therapy monitoring and management using a smartphone-enabled app
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study: 33497075

Group type: EXPERIMENTAL
Intervention: Intravenous administration of corticosteroids (10 mg dexamethasone 1 hour before and 24 hours after surgery, placebo periarticular injection)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Periarticular injection of corticosteroids (40 mg triamcinolone acetonide during surgery, placebo intravenous administration)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous administration of corticosteroids
Number of subjects: 100

Group type: COMPARATOR
Intervention: Periarticular injection of corticosteroids
Number of subjects: 100
Study: 34675112

Group type: EXPERIMENTAL
Intervention: I-PET after 4 cycles of R(R)-CHOP14
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: ΔSUVmax
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Deauville score (DS)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: aaIPI
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Low or low-intermediate aaIPI combined with ΔSUVmax > 70%
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: High-intermediate or high aaIPI combined with ΔSUVmax ≤ 70%
Number of subjects: 513
Study: 34898155

Group type: EXPERIMENTAL
Intervention: Topical stabilized cysteamine (st.Cys)
Number of subjects: 0
Study: 33213185

Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 403
Study: 32006642

Group type: EXPERIMENTAL
Intervention: Negatively framed message
Number of subjects: 52

Group type: COMPARATOR
Intervention: Positively framed message
Number of subjects: 52
Study: 35913721

Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 40
Study: 33012741

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) model trained on CAG videos
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: AI model
Number of subjects: 199
Study: 32176113

Group type: EXPERIMENTAL
Intervention: Interventional home‐based telerehabilitation group (ITG) using a wrist heart rate monitor, training at 70% to 80% of heart rate reserve for 60 minutes, 3 times a week for 12 weeks.
Number of subjects: 56

Group type: COMPARATOR
Intervention: Regular outpatient training group (ROT), training at 70% to 80% of heart rate reserve for 60 minutes, 3 times a week for 12 weeks under direct supervision.
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (ITG and ROT)
Number of subjects: 56
Study: 35598533

Group type: EXPERIMENTAL
Intervention: Epic sepsis prediction tool, education, and standardized order sets
Number of subjects: 6926

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6926
Study: 32578325

Group type: EXPERIMENTAL
Intervention: Spaced educational material
Number of subjects: 148
Study: 35428213

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Mobile Health Unit (MHU)
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) and Mobile Health Unit (MHU)
Number of subjects: 864
Study: 32100043

Group type: EXPERIMENTAL
Intervention: Opiate analgesics (medically prescribed or not)
Number of subjects: 8845

Group type: EXPERIMENTAL
Intervention: Opiate analgesics (not medically prescribed)
Number of subjects: 8845
Study: 32165156

Group type: EXPERIMENTAL
Intervention: BAL-directed CF therapy
Number of subjects: 141

Group type: COMPARATOR
Intervention: Standard CF therapy
Number of subjects: 141
Study: 35594613

Group type: EXPERIMENTAL
Intervention: 3rd line anti-EGFR therapy
Number of subjects: 1187

Group type: COMPARATOR
Intervention: TRIBE patients
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Systemic treatment after 2nd progression
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Systemic treatment after 3rd progression
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Systemic treatment after 4th progression
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: RAS/BRAF wild-type patients
Number of subjects: 1187
Study: 33006394

Group type: EXPERIMENTAL
Intervention: S5-methylation test
Number of subjects: 2661

Group type: EXPERIMENTAL
Intervention: S5-methylation test (cut-point 3.1)
Number of subjects: 2661

Group type: COMPARATOR
Intervention: HPV16/18
Number of subjects: 2661

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 2661

Group type: COMPARATOR
Intervention: HPV16/18 plus cytology
Number of subjects: 2661
Study: 32865375

Group type: EXPERIMENTAL
Intervention: Early rhythm control (treatment with antiarrhythmic drugs or atrial fibrillation ablation)
Number of subjects: 2789

Group type: COMPARATOR
Intervention: Usual care (limited rhythm control to management of atrial fibrillation-related symptoms)
Number of subjects: 2789

Group type: EXPERIMENTAL
Intervention: Early rhythm control
Number of subjects: 2789

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2789
Study: 35882513

Group type: EXPERIMENTAL
Intervention: Trabeculectomy (surgical management)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication (medical management)
Number of subjects: 0
Study: 34349165

Group type: EXPERIMENTAL
Intervention: Empathy triggering film sequence
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control film sequence
Number of subjects: 46
Study: 36294153

Group type: EXPERIMENTAL
Intervention: Partner support and initiating a planned quit attempt during treatment
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Lower baseline nicotine dependence and use of nicotine replacement
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: More restrictive residential smoking rules and lower children's TSE at baseline
Number of subjects: 327
Study: 35607441

Group type: EXPERIMENTAL
Intervention: Individualized nursing based on zero-defect theory
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conventional perioperative nursing care
Number of subjects: 174
Study: 33958973

Group type: EXPERIMENTAL
Intervention: CD28 genetic variant CD28-rs3116494
Number of subjects: 3253

Group type: EXPERIMENTAL
Intervention: CD80 genetic variant CD80-rs3850890
Number of subjects: 3253
Study: 32869511

Group type: EXPERIMENTAL
Intervention: Youth-friendly services (YFS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Youth-friendly services plus a mobile phone application (YFS + APP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (YFS)
Number of subjects: 200
Study: 33296222

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram based on CT images
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clinical factors model
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radiomics models (kNN, SVM, LR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 40
Study: 32256230

Group type: EXPERIMENTAL
Intervention: Alternative framework for asking clinical questions
Number of subjects: 100

Group type: COMPARATOR
Intervention: PICO framework for asking clinical questions
Number of subjects: 100
Study: 34699034

Group type: EXPERIMENTAL
Intervention: 3D HD imaging system
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2D 4K imaging system
Number of subjects: 40
Study: 33879131

Group type: EXPERIMENTAL
Intervention: Circumferential below-elbow cast
Number of subjects: 560

Group type: COMPARATOR
Intervention: Below-elbow plaster splint
Number of subjects: 560
Study: 32772383

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 36189733

Group type: EXPERIMENTAL
Intervention: Preoperative ACB
Number of subjects: 50

Group type: COMPARATOR
Intervention: Postoperative ACB
Number of subjects: 50
Study: 33782832

Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Number of subjects: 66

Group type: COMPARATOR
Intervention: SNAC alone
Number of subjects: 66
Study: 32788532

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) and Control Group (CG)
Number of subjects: 46
Study: 35622206

Group type: EXPERIMENTAL
Intervention: Morning fed (B)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Evening fasted (C)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Morning fasted (A)
Number of subjects: 41
Study: 32571602

Group type: EXPERIMENTAL
Intervention: Educational handout for self-management of stiffness
Number of subjects: 120

Group type: COMPARATOR
Intervention: One-on-one hand therapy in addition to the handout
Number of subjects: 120
Study: 32771678

Group type: EXPERIMENTAL
Intervention: tACS (gamma frequency, 40 Hz) - group 1: two 10-min stimulations per day for ten days
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: tACS (gamma frequency, 40 Hz) - group 2: one 20-min stimulation per day for ten days
Number of subjects: 6
Study: 34403836

Group type: EXPERIMENTAL
Intervention: DISC <1-month group
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: DISC 1-2-month group
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: DISC 3-5-month group
Number of subjects: 431

Group type: COMPARATOR
Intervention: Continuous group
Number of subjects: 431
Study: 34233376

Group type: EXPERIMENTAL
Intervention: Intervention according to the Progressively Lowered Stress Threshold (PLST) model
Number of subjects: 29
Study: 36242777

Group type: EXPERIMENTAL
Intervention: Cognitive Effort Discounting paradigm (Cog‐ED) under gain framing
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Cognitive Effort Discounting paradigm (Cog‐ED) under loss framing
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Cognitive Effort Discounting paradigm (Cog‐ED)
Number of subjects: 310
Study: 35587847

Group type: EXPERIMENTAL
Intervention: Ultra-hypo-fractionated radiotherapy (UHF, 42.7 Gy in 7 fractions, 3 days per week for 2.5 weeks)
Number of subjects: 879

Group type: COMPARATOR
Intervention: Conventional fractionation (CF, 78.0 Gy in 39 fractions, 5 days per week for 8 weeks)
Number of subjects: 879
Study: 34533489

Group type: EXPERIMENTAL
Intervention: Ceftobiprole (7.5 mg/kg for neonates and infants; 10-20 mg/kg for children 3 months to 17 years)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ceftobiprole (10-20 mg/kg with a maximum of 500 mg per dose every 8 hours for up to 14 days)
Number of subjects: 2
Study: 35033562

Group type: EXPERIMENTAL
Intervention: NICU2HOME app
Number of subjects: 298

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 298
Study: 32681219

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) fortnightly over 10 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intralesional meglumine antimoniate (MA) weekly over 10 weeks
Number of subjects: 30
Study: 35672873

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided curettage combined with hysteroscopic electro-resection after injection of pituitrin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hysteroscopic electro-resection after methotrexate chemotherapy
Number of subjects: 60
Study: 34282125

Group type: EXPERIMENTAL
Intervention: Prolonged-exposure psychotherapy with hydrocortisone augmentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged-exposure psychotherapy without hydrocortisone augmentation
Number of subjects: 0
Study: 33579256

Group type: EXPERIMENTAL
Intervention: One-stage revision procedure
Number of subjects: 96

Group type: COMPARATOR
Intervention: Two-stage revision procedure
Number of subjects: 96
Study: 34529050

Group type: EXPERIMENTAL
Intervention: CACS >1000 AU
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Low-attenuation plaque burden
Number of subjects: 1769

Group type: COMPARATOR
Intervention: Zero CACS
Number of subjects: 1769

Group type: EXPERIMENTAL
Intervention: Non-calcified and low-attenuation plaque burden
Number of subjects: 1769
Study: 33248750

Group type: EXPERIMENTAL
Intervention: Dry needling to the fibularis longus
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 50
Study: 33653149

Group type: EXPERIMENTAL
Intervention: Patching treatment for amblyopia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Monocular reading performance of treated amblyopes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fellow eye from treated amblyopes
Number of subjects: 10
Study: 32250167

Group type: EXPERIMENTAL
Intervention: R-CHOP/enzastaurin
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 0
Study: 35802818

Group type: EXPERIMENTAL
Intervention: Myths and facts education
Number of subjects: 152

Group type: COMPARATOR
Intervention: Facts only education
Number of subjects: 152
Study: 33395173

Group type: EXPERIMENTAL
Intervention: Scenario-based simulation training
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no simulation training)
Number of subjects: 122
Study: 612949064

Group type: EXPERIMENTAL
Intervention: Probiotics (once daily with breast milk)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (breast milk without probiotics)
Number of subjects: 108
Study: 34024551

Group type: EXPERIMENTAL
Intervention: Abbreviated Fat Tolerance Test (AFTT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 20
Study: 32207067

Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 4622
Study: 34473373

Group type: EXPERIMENTAL
Intervention: Gender-specific instruction for female first responders (10 min oral delivery by a staff physician)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control group (no gender-specific instruction)
Number of subjects: 364
Study: 34531573

Group type: EXPERIMENTAL
Intervention: Fully automated closed-loop glucose control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 0
Study: 32857060

Group type: EXPERIMENTAL
Intervention: SurgCare app
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional group (manual recording)
Number of subjects: 80
Study: 34406364

Group type: EXPERIMENTAL
Intervention: Bimekizumab (640 mg at week 0, 320 mg every 2 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Adalimumab (160 mg at week 0, 80 mg at week 2, 40 mg every week for weeks 4-10)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 90
Study: 33433609

Group type: EXPERIMENTAL
Intervention: Committers (362/1,313)
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Disengagers (576/1,313)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Tryers (375/1,313)
Number of subjects: 1313
Study: 36444905

Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35645073

Group type: EXPERIMENTAL
Intervention: WhatsApp-based oral health promotion programme
Number of subjects: 140
Study: 32957331

Group type: EXPERIMENTAL
Intervention: Sitting and lying Liuzijue
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine treatment and nursing
Number of subjects: 64
Study: 36170291

Group type: EXPERIMENTAL
Intervention: Aggressive virtual reality model (group AN)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Non-reactive virtual reality model (group NA)
Number of subjects: 16
Study: 33620480

Group type: EXPERIMENTAL
Intervention: Nurse-led educational intervention plus standard care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard pre-ICD implantation care
Number of subjects: 20